Journal Mobile Options
Table of Contents
Vol. 12, No. 4-5, 2003
Issue release date: September–October 2003
Section title: Review
Neurosignals 2003;12:221–229
(DOI:10.1159/000074624)

The Regulation of Cyclin-Dependent Kinase 5 Activity through the Metabolism of p35 or p39 Cdk5 Activator

Hisanaga S.-i. · Saito T.
Department of Biological Sciences, Graduate School of Science, Tokyo Metropolitan University, Tokyo, Japan

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Review

Received: 7/4/2003
Accepted: 9/5/2003
Published online: 12/18/2003

Number of Print Pages: 9
Number of Figures: 2
Number of Tables: 0

ISSN: 1424-862X (Print)
eISSN: 1424-8638 (Online)

For additional information: http://www.karger.com/NSG

Abstract

Cyclin-dependent kinase 5 (Cdk5) displays kinase activity predominantly in post-mitotic neurons and its physiological roles are unrelated to cell cycle progression. Cdk5 is activated by its binding to a neuron-specific activator, p35 or p39. The protein amount of p35 or p39 is a primary determinant of the Cdk5 activity in neurons, with the amount of p35 or p39 being determined by its synthesis and degradation. The expression of p35 is induced in differentiated neurons and is enhanced by extracellular stimuli such as neurotrophic factors or extracellular matrix molecules, specifically those acting on the ERK/Erg pathway. p35 is a short-lived protein and its degradation determines the life span. Degradation is mediated by the ubiquitin/proteasome system, similar to that for cyclins in proliferating cells. Autophosphorylation of p35 by Cdk5 is a signal for ubiquitination/degradation, and the degradation of p35 is triggered by glutamate treatment in cultured neurons. p35 is cleaved to p25 by calpain at the time of neuronal cell death, and this limited cleavage is suggested to be the cause of neurodegenerative diseases such as Alzheimer’s disease. Active Cdk5 changes the cellular localization by cleavage of p35 to p25; p35/Cdk5 is associated with membrane or cytoskeletons, but p25/Cdk5 is a soluble protein. Cleavage also increases the life span of p25 and changes the activity or substrate specificity of Cdk5. p25/Cdk5 shows higher phosphorylating activity to tau than p35/Cdk5 in a phosphorylation site-specific manner. Phosphorylation of p35 suppresses cleavage by calpain. Thus, phosphorylation of p35 modulates its proteolytic pattern, stimulates proteasomal degradation and suppresses calpain cleavage. Phosphorylation is age dependent, as p35 is phosphorylated in foetal brains, but unphosphorylated in adult brains. Therefore, foetal phosphorylated p35 is turned over rapidly, whereas adult unphosphorylated p35 has a long life and is easily cleaved to p25 when calpain is activated. p39 is also a short-lived protein and cleaved to the N-terminal truncation form of p29 by calpain. How the metabolism of p39 is regulated, however, is a future problem to be investigated.


Article / Publication Details

First-Page Preview
Abstract of Review

Received: 7/4/2003
Accepted: 9/5/2003
Published online: 12/18/2003

Number of Print Pages: 9
Number of Figures: 2
Number of Tables: 0

ISSN: 1424-862X (Print)
eISSN: 1424-8638 (Online)

For additional information: http://www.karger.com/NSG


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Nigg EA: Mitotic kinases as regulators of cell division and its checkpoints. Nature Rev Mol Cell Biol 2001;2:21–32.
  2. Tang D, Wang JH: Cyclin-dependent kinase 5 (Cdk5) and neuron-specific Cdk5 activators. Prog Cell Cycle Res 1996;2:205–216.
  3. Grant P, Sharma P, Pant HC: Cyclin-dependent protein kinase 5 (Cdk5) and the regulation of neurofilament metabolism. Eur J Biochem 2001;268:1534–1546.
  4. Dhavan R, Tsai LH: A decade of CDK5. Nat Rev Mol Cell Biol 2001;2:749–759.
  5. Hellmich MR, Pant HC, Wada E, Battey JF: Neuronal cdc2-like kinase: A cdc2-related protein kinase with predominantly neuronal expression. Proc Natl Acad Sci USA 1992;89:10867–10871.
  6. Lew J, Winkfein RJ, Paudel HK, Wang JH: Brain proline-directed protein kinase is a neurofilament kinase which displays high sequence homology to p34cdc2. J Biol Chem 1992;267:25922–25926.
  7. Meyerson M, Enders GH, Wu CL, Su LK, Gorka C, Nelson C, Harlow E, Tsai LH: A family of human cdc2-related protein kinases. EMBO J 1992;11:2909–2017.
  8. Tarricone C, Dhavan R, Peng J, Areces LB, Tsai LH, Musacchio A: Structure and regulation of the CDK5-p25 (nck5a) complex. Mol Cell 2001;8:657–669.
  9. Lew J, Huang QQ, Qi Z, Winkfein RJ, Aebersold R, Hunt T, Wang JH: A brain-specific activator of cyclin-dependent kinase 5. Nature 1994;371:423–426.
  10. Tsai L-H, Delalle I, Caniness VS, Chae T, Harlow E: p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. Nature 1994;371:419–423.
  11. Uchida T, Ishiguro K, Ohnuma J, Takamatsu M, Yonekura S, Imahori K: Precursor of cdk5 activator, the 23 kDa subunit of tau protein kinase II: Its sequence and developmental change in brain. FEBS Lett 1994;355:35–40.
  12. Zheng M, Leung CL, Liem RKH: Region-specific expression of cyclin-dependent kinase 5 (cdk5) and its activators, p35 and p39, in the developing and adult rat central nervous system. J Neurobiol 1998;35:141–159.
  13. Ohshima T, Ward JM, Huh CG, Longenecker G, Veeranna, Pant HC, Brady RO, Martin LJ, Kulkarni AB: Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc Natl Acad Sci USA 1996;93:11173–11178.
  14. Chae T, Kwon YT, Bronson R, Dikkes P, Li E, Tsai LH: Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron 1997;18:29–42.
  15. Ko J, Humbert S, Bronson RT, Takahashi S, Kulkarni AB, Li E, Tsai LH: p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J Neurosci 2001;21:6758–6871.
  16. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC Jr, Nairn AC, Greengard P: Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 1999;402:669–671.
  17. Floyd SR, Porro EB, Slepnev VI, Ochoa GC, Tsai LH, De Camilli P: Amphiphysin 1 binds the cyclin-dependent kinase (cdk) 5 regulatory subunit p35 and is phosphorylated by cdk5 and cdc2. J Biol Chem 2001;276:8104–8110.
  18. Tomizawa K, Ohta J, Matsushita M, Moriwaki A, Li ST, Takei K, Matsui H: Cdk5/p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity. J Neurosci 2002;22:2590–2597.
  19. Li BS, Sun MK, Zhang L, Takahashi S, Ma W, Vinade L, Kulkarni AB, Brady RO, Pant HC: Regulation of NMDA receptors by cyclin-dependent kinase-5. Proc Natl Acad Sci USA 2001;98:12742–12747.
  20. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH: Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999;402:615–622.
  21. Kusakawa G, Saito T, Onuki R, Ishiguro K, Kishimoto T, Hisanaga S: Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25. J Biol Chem 2000;275:17166–17172.
  22. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH: Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000;405:360–364.
  23. Nath R, Davis M, Probert AW, Kupina NC, Ren X, Schielke GP, Wang KKW: Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. Biochem Biophys Res Commun 2000;274:16–21.
  24. Lee M-H, Nikolic M, Baptista CA, Lai E, Tsai L-H, Massague J: The brain-specific activator p35 allows Cdk5 to escape inhibition by p27Kip1 in neurons. Proc Natl Acad Sci USA 1996;93:3259–3263.
  25. Qi Z, Huang QQ, Lee KY, Lew J, Wang JH: Reconstitution of neuronal Cdc2-like kinase from bacteria-expressed Cdk5 and an active fragment of the brain-specific activator. J Biol Chem 1995;270:10847–10854.
  26. Poon RY, Lew J, Hunter T: Identification of functional domains in the neuronal Cdk5 activator protein. J Biol Chem 1997;272:5703–5708.
  27. Lee KY, Rosales JL, Tang D, Wang JH: Interaction of cyclin-dependent kinase 5 (Cdk5) and neuronal Cdk5 activator in bovine brain. J Biol Chem 1996;271:1538–1543.
  28. Zukerberg LR, Patrick GN, Nikolic M, Humbert S, Wu CL, Lanier LM, Gertler FB, Vidal M, Van Etten RA, Tsai LH: Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron 2000;26:633–646.
  29. Sasaki Y, Cheng C, Uchida Y, Nakajima O, Ohshima T, Yagi T, Taniguchi M, Nakayama T, Kishida R, Kudo Y, Ohno S, Nakamura F, Goshima Y: Fyn and Cdk5 mediate semaphorin-3A signaling, which is involved in regulation of dendrite orientation in cerebral cortex. Neuron 2002;35:907–920.
  30. Huang D, Patrick G, Moffat J, Tsai LH, Andrews B: Mammalian Cdk5 is a functional homologue of the budding yeast Pho85 cyclin-dependent protein kinase. Proc Natl Acad Sci USA 1999;96:14445–14450.
  31. Nishizawa M, Kanaya Y, Toh-E A: Mouse cyclin-dependent kinase (Cdk) 5 is a functional homologue of a yeast Cdk, pho85 kinase. J Biol Chem 1999;274:33859–33862.
  32. Wu D-C, Yu Y-P, Lee NTK, Yu ACH, Wang JHC, Han Y-F: The expression of Cdk5, p35, p39, and Cdk5 kinase activity in developing, adult, and aged rat brains. Neurochem Res 2000;25:923–939.
  33. Fu WY, Wang JH, Ip NY: Expression of Cdk5 and its activators in NT2 cells during neuronal differentiation. J Neurochem 2002;81:646–654.
  34. Harada T, Morooka T, Ogawa S, Nishida E: ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat Cell Biol 2001;3:453–459.
  35. Munoz JP, Alvarez A, Maccioni RB: Increase in the expression of the neuronal cyclin-dependent protein kinase cdk-5 during differentiation of N2A neuroblastoma cells. Neuroreport 2000;11:2733–2738.
  36. Paglini G, Pigino G, Kunda P, Morfini G, Maccioni R, Quiroga S, Ferreira A, Caceres A: Evidence for the participation of the neuron-specific CDK5 activator p35 during laminin-enhanced axonal growth. J Neurosci 1998;18:9858–9869.
  37. Li B-S, Zhang L, Gu J, Amin ND, Pant HC: Integrin α1β1-mediated activation of cyclin-dependent kinase 5 activity is involved in neurite outgrowth and human neurofilament protein H Lys-Ser-Pro tail domain phosphorylation. J Neurosci 2000;20:6055–6062.
  38. Fu AK, Fu WY, Cheung J, Tsim KW, Ip FC, Wang JH, Ip NY: Cdk5 is involved in neuregulin-induced AChR expression at the neuromuscular junction. Nat Neurosci 2001;4:374–381.
  39. Tokuoka H, Saito T, Yorifuji H, Wei F, Kishimoto T, Hisanaga S: Brain-derived neurotrophic factor-induced phosphorylation of neurofilament-H subunit in primary cultures of embryo rat cortical neurons. J Cell Sci 2000;113:1059–1068.
  40. Dashiell SM, Tanner SL, Pant HC, Quarles RH: Myelin-associated glycoprotein modulates expression and phosphorylation of neuronal cytoskeletal elements and their associated kinases. J Neurochem 2002;81:1263–1272.
  41. Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS, Newell MK: Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003;5:118–125.
  42. Tanaka T, Veeranna, Ohshima T, Rajan P, Amin ND, Cho A, Sreenath T, Pant HC, Brady RO, Kulkarni AB: Neuronal cyclin-dependent kinase 5 activity is critical for survival. J Neurosci 2001;2:550–558.
  43. Ross S, Tienhaara A, Lee M-S, Tsai L-H, Gill G: GC box-binding transcription factors control the neuronal specific transcription of the cyclin-dependent kinase 5 regulator p35. J Biol Chem 2002;277:4455–4464.
  44. Ohshima T, Kozak CA, Nagle JW, Pant HC, Brady RO, Kulkarni AB: Molecular cloning and chromosomal mapping of the mouse gene encoding cyclin-dependent kinase 5 regulatory subunit p35. Genomics 1996;35:372–375.
  45. Zachariae W, Nasmyth K: Whose end is destruction: Cell division and the anaphase-promoting complex. Genes Dev 1999;13:2039–2058.
  46. Peters J-M: Subunits and substrates of the anaphase-promoting complex. Exp Cell Res 1999;248:339–349.
  47. Nakayama KI, Hatakeyama S, Nakayama K: Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27Kip1. Biochem Biophysic Res Commun 2001;282:853–860.
  48. Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH: p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitin-proteasome pathway. J Biol Chem 1998;273:24057–24064.
  49. Saito T, Ishiguro K, Onuki R, Nagai Y, Kishimoto T, Hisanaga S: Okadaic acid-stimulated degradation of p35, an activator of CDK5, by proteasome in cultured neurons. Biochem Biophys Res Commun 1998;252:775–778.
  50. Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttila T: Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35. Brain Res Mol Brain Res 2002;106:50–56.
  51. Saito T, Onuki R, Fujita Y, Kusakawa G, Ishiguro K, Bibb JA, Kishimoto T, Hisanaga S: Developmental regulation of the proteolysis of the p35 cyclin-dependent kinase 5 activator by phosphorylation. J Neurosci 2003;23:1189–1197.
  52. Ishiguro K, Takamatsu M, Tomizawa K, Omori A, Takahashi M, Arioka M, Uchida T, Imahori K: Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments. J Biol Chem 1992;267:10897–10901.
  53. Lew J, Winkfein RJ, Paudel HK, Wang JH: Brain proline-directed protein kinase is a neurofilament kinase which displays high sequence homology to p34cdc2. J Biol Chem 1992;267:25922–25926.
  54. Hisanaga S, Uchiyama M, Hosoi T, Yamada K, Honma N, Ishiguro K, Uchida T, Dahl D, Ohsumi K, Kishimoto T: Porcine brain neurofilament-H tail domain kinase: Its identification as cdk5/p26 complex and comparison with cdc2/cyclin B kinase. Cell Motil Cytoskeleton 1995;31:283–297.
  55. Tang D, Chun AC, Zhang M, Wang JH: Cyclin-dependent kinase 5 (Cdk5) activation domain of neuronal Cdk5 activator. J Biol Chem 1997;272:2318–2327.
  56. Wang X, Ching YP, Lam WH, Qi Z, Zhang M, Wang JH: Identification of a common protein association region in the neuronal Cdk5 activator. J Biol Chem 2000;275:31763–31769.
  57. Amin ND, Albers W, Pant HC: Cyclin-dependent kinase 5 (cdk5) activation requires interaction with three domains of p35. J Neurosci Res 2002;67:354–362.
  58. Wang KK: Calpain and caspase: Can you tell the difference? Trends Neurosci 2000;23:20–26.
  59. Sato K, Kawashima S: Calpain function in the modulation of signal transduction molecules. Biol Chem 2001;362:743–751.
  60. Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttila T: Cleavage of the cyclin-dependent kinase 5 activator p35 to p25 does not induce tau hyperphosphorylation. Biochem Biophys Res Commun 2002;298:693–698.
  61. Li G, Faibushevich A, Turunen BJ, Yoon SO, Georg G, Michaelis ML, Dobrowsky RT: Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. J Neurochem 2003;84:347–362.
  62. Hashiguchi M, Saito T, Hisanaga S, Hashiguchi T: Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau. J Biol Chem 2002;277:44525–44530.
  63. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T, Davies P, Burns M, Veeranna, Nixon R, Dickson D, Matsuoka Y, Ahlijanian M, Lau LF, Duff K: Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003;38:555–565.
  64. Taniguchi S, Fujita Y, Hayashi S, Kakita A, Takahashi H, Murayama S, Saido TC, Hisanaga S, Iwatsubo T, Hasegawa M: Calpain-mediated degradation of p35 to p25 in postmortem human and rat brains. FEBS Lett 2001;489:46–50.
  65. Takashima A, Murayama M, Yasutake K, Takahashi H, Yokoyama M, Ishiguro K: Involvement of cyclin-dependent kinase 5 activator p25 on tau phosphorylation in mouse brain. Neurosci Lett 2001;306:37–40.
  66. Yoo BC, Lubec G: p25 protein in neurodegeneration. Nature 2001;411:763–764.
  67. Tseng HC, Zhou Y, Shen Y, Tsai LH: A survey of Cdk5 activator p35 and p25 levels in Alzheimer’s disease brains. FEBS Lett 2002;523:58–62.
  68. Nguyen MD, Lariviere RC, Julien J-P: Deregulation of Cdk5 in a mouse model of ALS: Toxicity alleviated by perikaryal neurofilament inclusions. Neuron 2001;30:135–147
  69. Bu B, Li J, Davies P, Vincent I: Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci 2002;22:6515–6525
  70. Qi Z, Tang D, Zhu X, Fujita DJ, Wang JH: Association of neurofilament proteins with neuronal Cdk5 activator. J Biol Chem 1998;273:2329–2335.
  71. Veeranna, Shetty KT, Takahashi M, Grant P, Pant HC: Cdk5 and MAPK are associated with complexes of cytoskeletal proteins in rat brain. Brain Res Mol Brain Res 2000;76:229–236.
  72. Tang D, Yeng J, Lee K-Y, Matsushita M, Matsui H, Tomizawa K, Hatase O, Wang JH: An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. J Biol Chem 1995;270:26897–26903.
  73. Cai X-H, Tomizawa K, Tang D, Lu Y-F, Moriwaki A, Tokuda M, Nagahata S, Hatase S, Matsui H: Changes in the expression of nevel Cdk5 activator messenger RNA (p39nck5ai mRNA) during rat brain development. Neurosci Res 1997;28:355–360.
  74. Takahashi S, Saito T, Hisanaga S, Pant HC, Kulkarni AB: Tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules. J Biol Chem 2003;278:10506–10515.
  75. Jeong Y-G, Rosales JL, Marzban H, Sillitoe RV, Park D-G, Hawkes PR, Lee K-Y: The cyclin-dependent kinase 5 activator, p39, is expressed in stripes in the mouse cerebellum. Neuroscience 2003;118:323–334.
  76. Patzke H, Tsai L-H: Calpain-mediated cleavage of the cyclin-dependent kinase-5 activator p39 to p29. J Biol Chem 2002;277:8054–8060.
  77. Evans GI, Brown I, Whyte M, Harrington E: Apoptosis and the cell cycle. Curr Opin Cell Biol 1995;7:825–834.